COX-2基因沉默增强他莫昔芬抗乳腺癌活性的体内外研究
|
摘要
背景：
TAM作为选择性雌激素受体调节剂（selective estrogen receptormodulators, SERM），在临床上被广泛应用于早晚期乳腺癌的治疗及术后预防。然而另一方面，TAM能增加病人体内VEGF的水平，促进乳腺肿瘤新生血管的形成，因而限制了其功能，改善治疗策略成为一种必然。有研究表明塞来昔布（celecoxib, CXB）与TAM联合应用后，增强了TAM的抗肿瘤能力，并且降低了TAM剂量，显示出联合治疗的前瞻性意义。然而众所周知，CXB能引起胃肠道反应、肝损伤等并发症。利用RNAi技术，能有效沉默细胞中COX-2基因，从而诱导肿瘤细胞凋亡，抑制VEGF基因的表达，同时避免塞来昔布等药物产生的副作用。
目的：
在体外实验中，观察LV-COX-2和TAM单独及联合应用时对人乳腺癌MCF-7细胞株恶性生物学行为的影响（包括细胞增殖、凋亡、细胞周期分布、转移能力及侵袭性等），并检测对VEGF表达的影响；在体内试验中，构建人乳腺癌MCF-7裸鼠移植瘤模型，评估LV-COX-2与TAM联合治疗对肿瘤生长的抑制效果。通过体内外研究，观察二者协同及增敏作用，为日后临床应用提供理论依据。
方法：
1.根据RNAi设计原理及基因重组技术，针对COX-2基因的靶点序列设计、合成COX-2shRNA慢病毒载体，将其转染入人乳腺癌MCF-7细胞株，通过RT-PCR和Western blot法检测转染COX-2shRNA后，COX-2基因mRNA及蛋白质表达水平。
2.在体外实验中观察LV-COX-2、TAM治疗及二者联合作用时对人乳腺癌MCF-7细胞株生物学行为的影响，包括：MTT法检测细胞的增殖能力；AO/EB双荧光染色法检测细胞凋亡；流式细胞术检测细胞周期分布；Boyden小室及细胞划痕实验检测细胞迁移情况；Transwell法检测细胞的侵袭能力；ELISA及Western blot法检测PEG2、VEGF及VEGFR表达水平。
3.建立人乳腺癌MCF-7细胞裸鼠种植瘤模型，当肿瘤体积达到100-200mm3时，对各组荷瘤裸鼠给予不同的治疗手段，21d后取出肿瘤组织，测量瘤体重量和体积，观察LV-COX-2及TAM对裸鼠皮下种植瘤生长的影响。
结果：
1.成功构建针对COX-2基因的shRNA慢病毒载体，能够有效抑制人乳腺癌MCF-7细胞中COX-2基因mRNA及蛋白质表达。
2.体外实验证明，LV-COX-2与TAM治疗均能明显抑制人乳腺癌细胞株MCF-7细胞活力，抑制细胞增殖，诱导细胞凋亡及降低细胞的转移和侵袭力，二者联合作用时效果更为显著。
3.裸鼠体内试验证明，LV-COX-2和TAM治疗均能明显抑制MCF-7裸鼠移植瘤的生长，瘤体重量及体积明显减小，二者联合应用时效果更佳，优于任何一个单独治疗组。
结论：
研究发现，COX-2沉默联合TAM治疗能显著抑制体外人乳腺癌细胞株MCF-7细胞增殖，诱导细胞凋亡，同时亦明显抑制了裸鼠体内肿瘤的生长。此外，LV-COX-2和TAM联合治疗能够有效抑制血管内皮生长因子的表达及新生血管的形成。这些结果表明，LV-COX-2与TAM联合治疗在乳腺癌的抗转移和促凋亡研究中是一个很有前途的手段，二者联合应用具有协同和增敏作用，沉默COX-2基因增强了TAM的抗肿瘤活性。COX-2沉默联合TAM治疗是一个有潜能的治疗方案，尤其对于VEGF高表达的乳腺肿瘤来说。
Background：
Tamoxifen (TAM), a selective estrogen receptor modulator, is inwide clinical use for the treatment and prevention of breast cancer.However, extended TAM administration for breast cancer inducesincreased VEGF levels in patients, promoting new blood vessel formationand thereby limiting its efficacy and highlighting the need for improvedtherapeutic strategies. A recent study showed the combination ofcelecoxib(CXB) and TAM could achieve better antitumor activity bysuppressing VEGF expression and simultaneously could reduce doses ofTAM. However, it is known that the nonsteroidal antiinflammatorydrugs(NSAIDs), such as CXB, could result in liver injury, which wouldlimit their clinical applications. Cyclooxygenase-2(COX-2) silencing viaa replication-incompetent lentivirus (LV-COX-2) could induce cancerapoptosis, suppress VEGF gene expression and avoid the side effectsinduced by celecoxib.
Objective:
In this study, the effect of LV-COX-2infection, either alone or incombination with TAM, was analyzed in a breast cell lines forsuppressing VEGF expression and simultaneously reducing doses ofTAM. Cell proliferation, apoptosis, angiogenesis, metastasis, cell cycledistribution, an receptor signaling were determined after LV-COX-2combination with TAM treatment. In addition, tumor growth ability innude mice was detected to define the combination treatment effect in tumorigenesis in vivo. The objective of the present study was to evaluatethe effects of LV-COX-2in combination with TAM on the biologicalbehaviour of human breast cancer cell lines, MCF-7, in vitro and in vivo,and to reveal the underlying molecular mechanisms. These results wouldprovide theoretical base for clinical applications of LV-COX-2combinedwith TAM in future.
Methods:
1. To inhibit the expression of COX-2, a short hairpin RNA (shRNA)targeting the COX-2transcript was designed. The synthesizedoligonucleotides containing specific target sequence were cloned intopGCSIL-GFP lentivirus vector. The recombinant vector plasmids weretransfected into human breast cancer cell lines, MCF-7. The expression ofCOX-2mRNA and protein were detected by RT-PCR and Western blotrespectively.
2. To study the effects of COX-2gene silencing by RNAi and TAMon biological behaviour of human breast cancer MCF-7cells in vitro.MTT assay was used to detect ability of cell proliferation. Cells stainedwith acridine orange(AO) and ethidium bromide(EB) were observedunder fluorescence microscope in order to detect cell apoptosis. Flowcytometry was performed to detect the distribution of cells in thecell-cycle phases. Boyden Chamber and wound-healing assay as well astranswell filter were used to assess the migration and invasion ability ofthe cells. PGE2synthesis was determined by competitive enzyme-linkedimmunosorbent assay (ELISA). In addition, VEGF and VEGFR proteinexpression level were also measured by western blotting.
3. Exponentially growing MCF7cells were harvested and atumorigenic dose of2×106cells was injected intraperitoneally into4to5week-old female BALB mice. When tumors reached100-200mm3, mice were divided randomly into five groups.The control group received1%polysorbate resuspended in deionized water. The other four groups weretreated respectively with LV-NC, ATM, LV-COX-2, or ATM plusLV-COX-2intraperitoneally on alternative days for3weeks.The tumorsize was measured using caliper before the treatment injections weregiven and on the7th,14th and21th day of treatment. On21th day, theanimals were euthanized using chloroform, tumor tissue in nude miceswere collected, their volume and weight were measured, and the impactof COX-2silence on the growth of the implanted subcutaneously tumorin nude mice was analysised.
Results:
1. The recombinant lentiviral carrying a based shRNA againstCOX-2, LV-COX-2, were successfully constructed. LV-COX-2suppressed effectively the mRNA and protein expression of COX-2genein human breast cancer MCF-7cells.
2. The experiment results in virto demonstrated that LV-COX-2andTAM inhibited significantly the cell vibility and proliferation of MCF-7cells, induced cell apoptosis, and decreased the ability of the cellmigration and invasion. The effects of LV-COX-2in combination withTAM were higher than LV-COX-2and TAM treatment alone.
3. Silencing COX-2gene expression by LV-COX-2and TAMinhibited remarkably tumor growth in nude mices, and the tumor volumeand weight were significantly decreased. The combination withLV-COX-2and TAM got the better the results, compared toLV-COX-2and TAM alone.
Conclusion:
It is found that LV-COX-2combination with TAM treatment inbreast cancer cell significantly inhibited the proliferation and metastasis, and induced tumor apoptosis in vitro, and tumor growth also wassuppressed in vivo. In addition, we also found that LV-COX-2combination with TAM treatment could inhibit angiogenesis and VEGFexpression. Taken together, our experimental results indicate thatLV-COX-2combination with TAM has promising outcome inanti-metastatic and apoptotic studies, COX-2gene silencing can increasethe anti-tumor activity of TAM. Furthermore, these results showed thatLV-COX-2combination with TAM is a potential drug candidate fortreatment of breast tumors expressing high levels of VEGF.
TAM作为选择性雌激素受体调节剂（selective estrogen receptormodulators, SERM），在临床上被广泛应用于早晚期乳腺癌的治疗及术后预防。然而另一方面，TAM能增加病人体内VEGF的水平，促进乳腺肿瘤新生血管的形成，因而限制了其功能，改善治疗策略成为一种必然。有研究表明塞来昔布（celecoxib, CXB）与TAM联合应用后，增强了TAM的抗肿瘤能力，并且降低了TAM剂量，显示出联合治疗的前瞻性意义。然而众所周知，CXB能引起胃肠道反应、肝损伤等并发症。利用RNAi技术，能有效沉默细胞中COX-2基因，从而诱导肿瘤细胞凋亡，抑制VEGF基因的表达，同时避免塞来昔布等药物产生的副作用。
目的：
在体外实验中，观察LV-COX-2和TAM单独及联合应用时对人乳腺癌MCF-7细胞株恶性生物学行为的影响（包括细胞增殖、凋亡、细胞周期分布、转移能力及侵袭性等），并检测对VEGF表达的影响；在体内试验中，构建人乳腺癌MCF-7裸鼠移植瘤模型，评估LV-COX-2与TAM联合治疗对肿瘤生长的抑制效果。通过体内外研究，观察二者协同及增敏作用，为日后临床应用提供理论依据。
方法：
1.根据RNAi设计原理及基因重组技术，针对COX-2基因的靶点序列设计、合成COX-2shRNA慢病毒载体，将其转染入人乳腺癌MCF-7细胞株，通过RT-PCR和Western blot法检测转染COX-2shRNA后，COX-2基因mRNA及蛋白质表达水平。
2.在体外实验中观察LV-COX-2、TAM治疗及二者联合作用时对人乳腺癌MCF-7细胞株生物学行为的影响，包括：MTT法检测细胞的增殖能力；AO/EB双荧光染色法检测细胞凋亡；流式细胞术检测细胞周期分布；Boyden小室及细胞划痕实验检测细胞迁移情况；Transwell法检测细胞的侵袭能力；ELISA及Western blot法检测PEG2、VEGF及VEGFR表达水平。
3.建立人乳腺癌MCF-7细胞裸鼠种植瘤模型，当肿瘤体积达到100-200mm3时，对各组荷瘤裸鼠给予不同的治疗手段，21d后取出肿瘤组织，测量瘤体重量和体积，观察LV-COX-2及TAM对裸鼠皮下种植瘤生长的影响。
结果：
1.成功构建针对COX-2基因的shRNA慢病毒载体，能够有效抑制人乳腺癌MCF-7细胞中COX-2基因mRNA及蛋白质表达。
2.体外实验证明，LV-COX-2与TAM治疗均能明显抑制人乳腺癌细胞株MCF-7细胞活力，抑制细胞增殖，诱导细胞凋亡及降低细胞的转移和侵袭力，二者联合作用时效果更为显著。
3.裸鼠体内试验证明，LV-COX-2和TAM治疗均能明显抑制MCF-7裸鼠移植瘤的生长，瘤体重量及体积明显减小，二者联合应用时效果更佳，优于任何一个单独治疗组。
结论：
研究发现，COX-2沉默联合TAM治疗能显著抑制体外人乳腺癌细胞株MCF-7细胞增殖，诱导细胞凋亡，同时亦明显抑制了裸鼠体内肿瘤的生长。此外，LV-COX-2和TAM联合治疗能够有效抑制血管内皮生长因子的表达及新生血管的形成。这些结果表明，LV-COX-2与TAM联合治疗在乳腺癌的抗转移和促凋亡研究中是一个很有前途的手段，二者联合应用具有协同和增敏作用，沉默COX-2基因增强了TAM的抗肿瘤活性。COX-2沉默联合TAM治疗是一个有潜能的治疗方案，尤其对于VEGF高表达的乳腺肿瘤来说。
Background：
Tamoxifen (TAM), a selective estrogen receptor modulator, is inwide clinical use for the treatment and prevention of breast cancer.However, extended TAM administration for breast cancer inducesincreased VEGF levels in patients, promoting new blood vessel formationand thereby limiting its efficacy and highlighting the need for improvedtherapeutic strategies. A recent study showed the combination ofcelecoxib(CXB) and TAM could achieve better antitumor activity bysuppressing VEGF expression and simultaneously could reduce doses ofTAM. However, it is known that the nonsteroidal antiinflammatorydrugs(NSAIDs), such as CXB, could result in liver injury, which wouldlimit their clinical applications. Cyclooxygenase-2(COX-2) silencing viaa replication-incompetent lentivirus (LV-COX-2) could induce cancerapoptosis, suppress VEGF gene expression and avoid the side effectsinduced by celecoxib.
Objective:
In this study, the effect of LV-COX-2infection, either alone or incombination with TAM, was analyzed in a breast cell lines forsuppressing VEGF expression and simultaneously reducing doses ofTAM. Cell proliferation, apoptosis, angiogenesis, metastasis, cell cycledistribution, an receptor signaling were determined after LV-COX-2combination with TAM treatment. In addition, tumor growth ability innude mice was detected to define the combination treatment effect in tumorigenesis in vivo. The objective of the present study was to evaluatethe effects of LV-COX-2in combination with TAM on the biologicalbehaviour of human breast cancer cell lines, MCF-7, in vitro and in vivo,and to reveal the underlying molecular mechanisms. These results wouldprovide theoretical base for clinical applications of LV-COX-2combinedwith TAM in future.
Methods:
1. To inhibit the expression of COX-2, a short hairpin RNA (shRNA)targeting the COX-2transcript was designed. The synthesizedoligonucleotides containing specific target sequence were cloned intopGCSIL-GFP lentivirus vector. The recombinant vector plasmids weretransfected into human breast cancer cell lines, MCF-7. The expression ofCOX-2mRNA and protein were detected by RT-PCR and Western blotrespectively.
2. To study the effects of COX-2gene silencing by RNAi and TAMon biological behaviour of human breast cancer MCF-7cells in vitro.MTT assay was used to detect ability of cell proliferation. Cells stainedwith acridine orange(AO) and ethidium bromide(EB) were observedunder fluorescence microscope in order to detect cell apoptosis. Flowcytometry was performed to detect the distribution of cells in thecell-cycle phases. Boyden Chamber and wound-healing assay as well astranswell filter were used to assess the migration and invasion ability ofthe cells. PGE2synthesis was determined by competitive enzyme-linkedimmunosorbent assay (ELISA). In addition, VEGF and VEGFR proteinexpression level were also measured by western blotting.
3. Exponentially growing MCF7cells were harvested and atumorigenic dose of2×106cells was injected intraperitoneally into4to5week-old female BALB mice. When tumors reached100-200mm3, mice were divided randomly into five groups.The control group received1%polysorbate resuspended in deionized water. The other four groups weretreated respectively with LV-NC, ATM, LV-COX-2, or ATM plusLV-COX-2intraperitoneally on alternative days for3weeks.The tumorsize was measured using caliper before the treatment injections weregiven and on the7th,14th and21th day of treatment. On21th day, theanimals were euthanized using chloroform, tumor tissue in nude miceswere collected, their volume and weight were measured, and the impactof COX-2silence on the growth of the implanted subcutaneously tumorin nude mice was analysised.
Results:
1. The recombinant lentiviral carrying a based shRNA againstCOX-2, LV-COX-2, were successfully constructed. LV-COX-2suppressed effectively the mRNA and protein expression of COX-2genein human breast cancer MCF-7cells.
2. The experiment results in virto demonstrated that LV-COX-2andTAM inhibited significantly the cell vibility and proliferation of MCF-7cells, induced cell apoptosis, and decreased the ability of the cellmigration and invasion. The effects of LV-COX-2in combination withTAM were higher than LV-COX-2and TAM treatment alone.
3. Silencing COX-2gene expression by LV-COX-2and TAMinhibited remarkably tumor growth in nude mices, and the tumor volumeand weight were significantly decreased. The combination withLV-COX-2and TAM got the better the results, compared toLV-COX-2and TAM alone.
Conclusion:
It is found that LV-COX-2combination with TAM treatment inbreast cancer cell significantly inhibited the proliferation and metastasis, and induced tumor apoptosis in vitro, and tumor growth also wassuppressed in vivo. In addition, we also found that LV-COX-2combination with TAM treatment could inhibit angiogenesis and VEGFexpression. Taken together, our experimental results indicate thatLV-COX-2combination with TAM has promising outcome inanti-metastatic and apoptotic studies, COX-2gene silencing can increasethe anti-tumor activity of TAM. Furthermore, these results showed thatLV-COX-2combination with TAM is a potential drug candidate fortreatment of breast tumors expressing high levels of VEGF.
引文
[1]Jordan VC and O'Malley BW. Selective estrogen-receptor modulatorsand antihormonal resistance in breast cancer[J]. Clin Oncol,2007,25:5815-5824.
[2]Brauch H and Jordan VC. Targeting of tamoxifen to enhanceantitumour action for the treatment and prevention of breast cancer: the'personalised' approach?[J]. Eur Cancer,2009,45:2274-2283.
[3]Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen andradiotherapy in women with locally excised ductal carcinoma in situ:long-term results from the UK/ANZ DCIS trial. Lancet Oncol,2011,12:21-29.
[4]Roberts CG, Millar EK, O'Toole SA, et al. Identification of PUMA asan estrogen target gene that mediates the apoptotic response totamoxifen in human breast cancer cells and predicts patient outcomeand tamoxifen responsiveness in breast cancer[J]. Oncogene,2011,30:3186-3197.
[5]Garvin S, Nilsson UW and Dabrosin C. Effects of oestradiol andtamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2in breast cancerand endothelial cells. Br J Cancer,2005,93:1005-1010.
[6]Qu Z, Van Ginkel S, Roy AM, et al. Vascular endothelial growth factorreduces tamoxifen efficacy and promotes metastatic colonization anddesmoplasia in breast tumors[J]. Cancer Res,2008,68:6232-6240.
[7]Majeti BK, Lee JH, Simmons BH and Shojaei F. VEGF is animportant mediator of tumor angiogenesis in malignant lesions in agenetically engineered mouse model of lung adenocarcinoma[J]. BMCCancer,2013,13:213.
[8]Chen CT and Hung MC: Beyond anti-VEGF. Dual-targetingantiangiogenic and antiproliferative therapy. Am J Transl Res,2013,5:393-403.
[9]Breinig M, Schirmacher P and Kern MA. Cyclooxygenase-2(COX-2)——a therapeutic target in liver cancer?[J]. Curr Pharm Des,2007,13:3305-3315.
[10]Stasinopoulos I, O'Brien DR, Wildes F, Glunde K and Bhujwalla ZM.Silencing of cyclooxygenase-2inhibits metastasis and delays tumoronset of poorly differentiated metastatic breast cancer cells[J]. MolCancer Res,2007,5:435-442.
[11]Heer P, Sandel MH, Guertens G, et al. Celecoxib inhibits growth oftumors in a syngeneic rat liver metastases model for colorectalcancer[J]. Cancer Chemother Pharmacol,2008,62:811-819.
[12]Narayanan BA, Narayanan NK, Davis L, and Nargi D. RNAinterference-mediated cyclooxygenase-2inhibition prevents prostatecancer cell growth and induces differentiation: modulation ofneuronal protein synaptophysin, cyclin D1, and androgen receptor[J].Mol Cancer Ther,2006,5:1117-1125.
[13]Singh-Ranger G, Salhab M and Mokbel K. The role ofcyclooxygenase-2in breast cancer: review[J]. Breast Cancer ResTreat,2008,109:189-198.
[14]Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelialgrowth factor and angiogenesis[J]. Pharmacol Rev,200456:549-580.
[15]Hasegawa K, Ichikawa W, Fujita T, et al. Expression ofcyclooxygenase-2(COX-2) mRNA in human colorectal adenomas.Eur J Cancer,2001,37:1469-1474.
[16]Kumar BN, Rajput S, Dey KK, et al. Celecoxib alleviatestamoxifen-instigated angiogenic effects by ROS-dependentVEGF/VEGFR2autocrine signaling[J]. BMC Cancer,2013,13:273.
[17]Lacroix I, Lapeyre-Mestre M, Bagheri H, et al. Nonsteroidalanti-inflammatory drug-induced liver injury: a case-control study inprimary care[J]. Fundam Clin Pharmacol,2004,18:201-206.
[18]Rudnick DA, Shikapwashya O, Blomenkamp K and Teckman JH.Indomethacin increases liver damage in a murine model of liverinjury from alpha-1-antitrypsin deficiency[J]. Hepatology,2006,44:976-982.
[19]Park JW, Park JE, Lee JA, Lee CW and Kim CM. Cyclooxygenase-2(COX-2) is directly involved but not decisive in proliferation ofhuman hepatocellular carcinoma cells[J]. Cancer Res Clin Oncol,2006,132:184-192.
[20]Wang R, Wang X, Lin F, Gao P, Dong K and Zhang HZ.shRNA-targeted cyclooxygenase (COX)-2inhibits proliferation,reduces invasion and enhances chemosensitivity in laryngealcarcinoma cells[J]. Mol Cell Biochem,2008,317:179-188.
[21]Lin T, Gu J, Zhang L, et al. Enhancing adenovirus-mediated genetransfer in vitro and in vivo by addition of protamine andhydrocortisone[J]. Gene Med,2003,5:868-875.
[22]Kase S, Osaki M, Honjo S, et al. Expression of cyclooxygenase-1andcyclooxygenase-2in human esophageal mucosa, dysplasia andcarcinoma[J]. Pathobiology,2004,71(2):84-92.
[23]Swami S, Krishnan AV, Moreno J, et al. Calcitriol and genisteinactions to inhibit the prostaglandin pathway: potential combinationtherapy to treat prostate cancer[J]. J Nutr,2007,137(1Suppl):205S-210S.
[24]Denkert C, Winzer KJ, Muller BM, et al. Elevated expression ofcyclooxygenase-2is a negative prognostic factor for disease-freesurvival and overall survival in patients with breast carcinoma[J].Cancer,2003,97(12):2978-2987.
[25]Thill M, Fischer D, Kelling K, et al. Expression of vitamin Dreceptor(VDR), cycloloxygenase-2(COX-2) and15-hydro xyprosta-glandin dehydrogenase (15-PGDH) in benign and malignant ovariantissue and25-hydroxycholecalciferol (25(OH2)D3) and prostaglandinE2(PEG2) serum level in ovarian cancer patient[J].Steroid BiochemMol Biol,2010,121(1-2):387-390.
[26]Subbaramaiah K and Dannenberg AJ. Cyclooxygenase-2: a moleculartarget for cancer prevention and treatment[J]. Trends Pharmacol Sci,2003,24(2):96-102.
[27]Singh-Ranger G, Salhab M and Mokbel K. The role ofcyclooxygenase-2in breast cancer: review[J]. Breast cancer Res Treat,2008,109(2):189-198.
[28]Singh B, Cook KR, Vincent L, et al. Role of COX-2intumorospheres derived from al breast cancer cell line[J]. J Surg Res,2011,168(1): e39-49.
[29]Mauro A, Lipari L, Leone A, et al. Expression of cyclooxygenase-1and cyclooxygenase-2in normal and pathological human oralmucosa[J]. Folia Histochem Cytobiol.2010,48(4):555-563.
[30]Sobolewski C, Cerella C, Dicato M, et al. The role ofcyclooxygenas-2in cell proliferation and cell death in humanmalignancies[J]. Int J Cell Biol,2010,2010:215158.
[31]Sakamoto A, Yokoyama Y, Umemoto M. Clinical implication ofexpression of cyclooxygenase-2and peroxisome proliferatoractivated-receptor g in epithelial ovarian tumours[J]. British Journalof Cancer,2004,91(14),633–638.
[32]Ghosh N, Chaki R, Mandal V, et al. COX-2as a target for cancertherapy[J]. Pharmacological Reports,2010,62(2):233-244.
[33]Joki T，Heese O，Nikas DC，et al. Expression of cyclooxygenas-2(COX-2) in human glioma and in vitro inhibition by a specific COX-2inhibitor,NS2398[J]. Cancer Res,2000,60(17):4926-4931.
[34]Mehar A, Macanas Pirard P, Mizokami AT, et al. The effects ofcyclooxygenase-2expression in prostate cancer cells: modulation ofresponse to cytotoxic agents[J]. J Pharmacol Exp Ther,2008,324(3):1181-1187.
[35]Frasor J, Weaver AE, Pradhan M, et al. Synergistic up-regulation ofprostaglandin E synthase expression in breast cancer cells by17beta-estradiol and proinflammatory cytokines[J]. Endocrinology,2008,149(12):6272-6279.
[36]Oshima H, Oshima M. The inflammatory network in thegastrointestinal tumor microenvironment: lessons from mouse models[J]. Gastroenterol,2012,47(2):97-106.
[37]Khan Z, Khan N, Tiwari RP, et al. Biology of COX-2: An Applicationin Cancer Therapeutics[J]. Current Drug Targets,2011,12(7):1082-1093.
[38]Athanassiadou P, Grap sa D, Athanassiades P, et al. The prognosticsignificance of COX-2and survivin expression in ovaian cancer[J].Pathol Res Pract,2008,204(4):241-249.
[39]Daikoku T, Tranguch S, Trofimova N, et al. Cyclooxygenase-1isoverexpressed in multiple genetically engineered mouse models ofepithelial ovarian cancer[J]. Cancer Res,2006,66(5):2527-2531.
[40]Ko SH, Choi GJ, Lee JH, et al. Differential effects of selectivecyclooxygenase-2inhibitors in inhibiting proliferation and inductionof apoptosis in oral squamous cell carcinoma[J]. OncolRep,2008,19(2):425-433.
[41]Basu GD, Pathangey LB, Tinder TL, et al. Cyclooxygenase-2inhibitor induces apoptosis in breast cancer cells in an in vivo modelof spontaneous metastatic breast cancer[J].Mol Cancer Res,2004,2(11):632-642.
[42]杨晓文,崔明,王世清,等.乳腺癌组COX-2和Bcl-2蛋白表达及其临床意义[J].中华肿瘤防治杂志,2009,16(4):295-298.
[43]Elder DJ, Halto n DE, Cr ew T E, et al. Apoptosis induction andcyclooxygenase-2regulation in human colorectal adenoma andcarcinoma cell lines by the cy cloox genease-2-selective no nsteroedalanti-inflammatory drugs NS-398. I nt J Cancer,2000,86(4):553-560.
[44]Kundu N, Smyth MJ, Samsel L, et al. Cyclooxygenase inhibitorsblock cell growth, increase ceramide and inhibit cell cycle[J]. BreastCancer Res Treat,2002,76(1):57-64.
[45]Trifan OC, Smith RM, Thompson BD, et al. Overexpression ofcyclooxygenase-2induceds cell cycle arrest[J]. J Biol Chem,1999,274(48):34141-34147
[46]Lee JS, Choi YD, Lee JH, et al. Expression of cyclooxygenase-2inepithelial ovarian tumors and its relation to vascular endothelialgrowth factor and p53expression[J]. Int J Gynecol Cancer,2006,16Suppl1:247-253.
[47]徐晓辉,申爱荣,王志红. COX-2、VEGF及MMP-9蛋白在上皮性卵巢癌组织中的表达及意义[J].肿瘤基础与临床,2010,23(6)：467-469.
[48]Ferrandina G,Ranelletti FO, Martinelli E et al. Cyclooxygenase-2(Cox-2)expression and resistance to platinum versusplatinum/paclitaxel containing chemotherapy in advanced ovariancancer[J]. BMC Cancer,2006,11(6):182.
[49]Raspollini MR, Amunni G, Villanucci A, et al. COX-2status inrelation to tumor microvessel density and VEGF expression: analysisin ovarian carcinoma patients with low versus high survival rates[J].Oncol Rep.2004,11(2):309-313.
[50]Fujimoto J Toyoki H, Sakaguchi H, et al. Clinical implications ofexpression of cyclooxygenase-2related to angiogenesis in ovariancancer[J]. Oncol Rep,2006,15(1):21–25.
[51]Form DM, Auerbach R. PGE2and angiogenesis[J]. Proc Soc ExpBiol Med,1983,172(2):214–218.
[52]Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN.Cyclooxygenase regulates angiogenesis induced by colon cancercells[J]. Cell,1998,93(5):705–716.
[53]Zhu YM, Azahri NS, Yu DC, et al. Effects of COX-2inhibition onexpression of vascular endothelial growth factor and interleukin-8inlung cancer cells[J]. BMC Cancer,2008,8(7):218
[54]Wu Y, Wei zw, He YL. Efficacy of adjuvant XELOX and FOLFOX6chemotherapy after D2dissection for gastric cancer[J]. World JGastroenterol,2013,19(21):3309-3315.
[55]Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancercyclooxygenase-2-dependent invasion is mediated by CD44[J]. JBiol Chem,2011,276(24):20809-20812.
[56]Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact withosteoblasts to support osteoclast formation [J]. Endocrinology,1999;140(10):4451-4458.
[57]Tsujii M, Kawano S, Tsuji S, Saw aoka, et al. Cyclooxygeneaseregulates angiogenesis induced by coloncancer cells. Cell,1998,93(2):705-716.
[58]Lim SC. Role of COX-2, VEGF and cyclin D1in mammaryinfiltrating duct carcinoma [J]. Oncol Rep,2003,10(5):1241-1249.
[59]Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancercyclooxygenase-2-dependent invasion is mediated by CD44[J]. JBiol Chem,2001;276(24):20809-20812.
[60]Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell anddendritic cell function is related to Cyclooxygenase-2overexpressionand prostaglandin E (2) secretion in patients with breast cancer [J].Ann Surg Oncol,2004;11(3):328-339.
[61]Stolina M, Sharma S, Lin Y, et al. Specific inhibition ofcyclooxygenase-2restores antitumor reactivity by altering the balanceof IL-10and IL-12synthesis [J]. Immunology,2000;164(1):361-370.
[62]Pockaj BA, Basu GD, Pat hangey LB, et al. Reduced T-cell anddendritic cell function is related to cyclooxygenase-2overexpressionand prostag land ine secretion in patients with breast cancer[J]. AnnSurg Oncol,2004,11(3):328-329.
[63]Banerjec S, Bueso-Ramos C, Aggarwal BB. Suppression of7,12-dimethylbenz (a) anthracene-induced mammary carcinogensis inrats by reveratrol: role of nuclear factor-kappa B, Cyclooxygenase-2,and matrix metaloprotease9[J]. Cancer Res,2002;62(17):4945-4954.
[64]Wiese FW, Thompson PA, Kadlubar FF, et al. Carcinogen substratespecificity of human COX-1and COX-2[J]. Carcinogenesis,2001;22(1):5-10.
[65]Stolina M, Shanna S, Lin Y， et al. Secific inhibition ofcyclooxygenase-2restores antiturcar reactivity by altering the balanceof IL-10and II-12synthesis[J]. J Immunol,2000,164(1):361.
[66]Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterifiedarachidonic acid signals apoptosis [J]. Proc Natl Acad Sci USA,2000;97(21):11280-11285.
[67]Brueggenmeier RW, Quinn AL, Parrett ML. Correlation of aromataseand cyclooxygenase gene expression in human breast cancerspecimens [J]. Cancer Lett,1999;140(1-2):27-35.
[68]Oliveira VM, Piato S, Silva MA. Correlat ion of cyclooxygenase-2and aromatase immuno-histochemical expression in invasive ductalcarcinoma,ductal carcinoma in situ, and adjacent normal epithelium[J]. Breast Cancer ResTreat,2006,95(3):235-241.
[69]Sa lhabM, Singh-Range rG, Moke lb R, et al Cyc looxygenase-2mRNA expression correlates with a rom a tase expression in hum anbreast cancer[J]. Surg Oncol,2007,96(5):424-428
[70]Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance ofelevaluted cyclooxygenase-2expression in breast cancer [J]. CancerRes,2002;62(3):632-635.
[71]Hee S, Hyeong M, Wonshik H, et al. COX2overexpression is aprognostic marker for Stage III breast cancer[J]. Breast Cancer ResTreat (2012)132:51–59
[72]Barnes N,Haywood P,Flint P, et al.Survivin expression in in situ andinvasive breast cancer relates to COX-2expression and DCISrecurrence [J]. Br J Cancer,2006,94:253-258.
[73]Sivula, Talvensaari, Johan, et al. Association of cyclooxygenase-2and matrix metalloproteinase-2expression in human breast cancer[J].Breast Cancer Res Treat,2005,89(3):215-220.
[74]吴骥,管小青,顾书成,等. COX-2及Ki67在乳腺癌浸润性导管癌组织中的表达及临床意义[J].中国肿瘤外科杂志,2013,10(5):296-299.
[75]李莉,祝峙,方国恩等. COX-2和P53在乳腺癌组织中的表达及其相关性[J].中华肿瘤防治杂志,2006,13(4):287-289.
[76]王西京,代志军,赵世平,等.乳腺癌组织中环氧化酶-2的表达及其意义[J].肿瘤防治杂志,2004,11(12):1261-1263.
[77]Kelly LM, Hill AD, Kennedy S, et al. Lack of prognostic effect ofCox-2expression in primary breast cancer on short-term follow-up.Eur J Surg Oncol,2003,29:707–710.
[78]Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJCOX-2expression is associated with an aggressive phenotype inductalcarcinoma in situ. Br J Cancer,2004,90:423–429.
[79]Mohammad AM, Abdel HA, Abdel W, et al. Expression ofcyclooxygenase-2and12-lipoxygenase in human breast cancer andtheir relationship with HER-2/neu and hormonal receptors: impact onprognosis and therapy. Indian J Cancer,2006,43:163–168
[80]Denkert C, Winzer KJ, Muller BM, et al. Elevated expression ofcyclooxygenase-2is a negative prognostic factor for disease freesurvival and overall survival in patients with breast carcinoma[J].Cancer,2003,97:2978–2987.
[81]Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase2expression is associated with angiogenesis and lymph node metastasisin human breast cancer[J]. Clin Pathol,2002,55:429–434.
[82]O’Connor JK, Avent J, Lee RJ, et al. Cyclooxygenase-2expressioncorrelates with diminished survival in invasive breast cancer treatedwith mastectomy and radiotherapy[J]. Radiat Oncol Biol Phys,2004,58:1034–1040.
[83]Hee SK, Hyeong GM, Wonshik H, et al. COX2overexpression is aprognostic marker for Stage III breast cancer[J]. Breast Cancer ResTreat,2012,132:51-59.
[84]Sym SJ, Chang HM, Ryn MH, et al. Neoadjuvant docetaxel,capecitabine and cisplain(DXP) in patients with unresectable locallyadvanced or metastatic gastric cancer[J]. Ann Surg Oncol,2010,17(4):1024-1032.
[85]Haffty B, Yang Q, Moran M, et al. Estrogendependent prognosticsignificance of cyclooxygenase-2expression in early-stage invasivebreast cancers treated with breast conserving surgery and radiation.Int J Radiat Oncol Biol Phys,2008,71:1006–1013.
[86]Park K, Han S, Shin E, Kim HJ, Kim JY.Cox-2expression on tissuemicroarray of breast cancer[J]. Eur J Surg Oncol,2006,32:1093–1096.
[87]Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancermetastasis to the brain[J]. Nature,2009,459:1005–1009.
[88]Singh B, Berry JA, Shoher A, et al. COX-2involvement in breastcancer metastasis to bone[J]. Oncogene,2007,26:3789–3796.
[89]肖锋,顾春燕,姚建国,等. COX-2和VEGF-C基因在乳腺癌良恶性病变中的表达研究[J].实用肿瘤杂志,2011,26(6):573-576.
[90]王彬,聂国庆,张超,等. COX-2与突变型P53蛋白在乳腺癌组织中的表达及临床意义[J].实用肿瘤杂志,2010,25(3):295-299.
[91]管小青,顾书成,吴骥,等.生存素和COX-2在乳腺癌复发及转移癌组织的表达[J].江苏医药,2012,38(1):33-35.
[92]王群,余明华,王耕,等. DLL4、COX-2和MMP2在乳腺癌组织中的表达及临床意义[J].临床肿瘤学杂志,2012,9(17):814-817.
[93]Davies G, Salter J, Hill M, et al. Correlation betweencyclooxygenase-2expression and angiogenesis in human breastcancer [J]. Clin Cancer Res,2003,9(7):2651-2656.
[94]Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2expression inhuman breast cancers and adjacent ductal carcinoma in situ[J]. CancerRes,2002,62(6):1676-1681.
[95]Rao PN, Grover RK. Apricoxib. A COX-2inhibitor for the potentialtreatment of pain and cancer[J]. The investigational drugs journal(IDrugs),2009,12(11):711-722.
[96]Abbadessa G, Spaccamiglio A, Sartori ML, et al. The aspirinmetabolite, salicylate, inhibits7,12-dimethylbenz[a] anthracene-DNAadduct formation in breast cancer cells[J]. Int J Oncol,2006,28(5):1131-1140.
[97]Abou-Issa HM, AIshafie GA, Seibert K, et al. Dose-response effectsof the COX-2inhibitor, celecoxib, on the chemoprevention ofmammary carcinogenesis[J]. Anticancer Res,2001,21(5):3425-3432.
[98]Khuder SA, Mutgi AB. Breast cancer and NSAIDuse:ameta-anaylysis[J]. Br J Cancer,2001,84(9):1188-1192.
[99]Sharpe CR, Collet JP, McNutt M, et al. Nested case control study ofthe effects of non-steroidal anti-inflammatory drugs on breast cancerrisk and stage[J]. Br J Cancer,2000,83(1):112-120.
[100]Harris RE, Kasbari Farrar WB. Prospective study of nonsteroidalanti-inflammatiory drugs and breast cancer[J]. Oncol Rep,1996,6:71-73.
[101]Alshafie GA, Abou-Issa HM, Seibert K and Harris RE.Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2inhibitor, in a rat mammary tumor model[J]. Oncol Rep,2000,7(6):1377-1381.
[102]Harris RE, Alshafie GA, Abou-Issa H and Seibert K.Chemoprevention of breast cancer in rats by celecoxib, acyclooxygenase-2inhibitor[J]. Cancer Res,2000,60(8):2101-2103.
[103]Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2inhibition: effects on tumor growth, cell cycling andlymphangiogenesis in a xenograft model of breast cancer[J]. Br JCancer,2007,96(4):575-582.
[104]Yoshinaka R, Shibata MA, Morimoto J, et al. COX-2inhibitorcelecoxib suppresses tumor growth and lung metastasis of a murinemammary cancer[J]. Anticancer Res,2006.26(6B):4245-4254.
[105]Moreno J, Krishnan AV, Swami S, et al. Regulation ofprostaglandin metabolism by calcitriol attenuates growth stimulationin prostate cancer cells[J]. Cancer Res,2005,65(17):7917-7925.
[106]Kang HF, Wang XJ, Liu XX, et al. Chemopreventive effect ofcelecoxib against DMBA-induced breast cancer and itsmechanism[J]. Nan Fang Yi Ke Da Xue Xue Bao,2006,26(11):1599-1602.
[107]何美蓉,林劲松,宋于刚.选择性COX-2抑制剂对大鼠胃溃疡微血管形成的影响及机制[J].广东医学,2008,29(3):379-381.
[108]李根,陈虹.选择性COX-2抑制剂塞来昔布抗癌作用研究进展[J].Journal of Logistics University of CAPF(Medical Sciences),2012,21(3):214-220.
[109]Xiuling Lu, Melissa D. Howard, Dominique R. Talbert, et al.Nanoparticles Containing Anti-inflammatory Agents as ChemotherapyAjuvants: Role of Plasma Esterases in Drug Release [J]. AAPSJ.Mar2009,11(1):120-122.
[110]Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular eventsassociated with rofecoxib in a colorectal Adenoma chemopreventiontrial[J]. N Engl J Med,2005,352(11):1092-1102.
[111]Chen LC, Ashcroft DM. Risk of myocardial infarction associatedwith selective COX-2inhibitors meta-analysis of randomisedcontrolled trials[J].Pharmacoepeidemiol Drug Saf,2007,16(7):762-772.
[112]Farooq M, Haq I, Qureshi AS. Cardiovescular risks of COXinhibition: current perspectives [J]. Expert Opin Pharmacother,2008,9(8):1311-1319.
[113]钟英强,黄花荣,刘娟,等. siRNA沉默COX-2基因对人胰腺癌Capan-2细胞增殖、细胞周期、凋亡和成瘤能力的影响[J].中国病理生理杂志,2011,27(7):1290-1296.
[114]药立波.医学分子生物学[M].北京:人民卫生出版社,2004：290-292.
[115]Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAsand siRNAs[J]. Cell,2009,136(4):642-655.
[116]Nagvi AR,Islam MN, Choudhury NR, et al. the fascinating worldof RNA interference[J].Int J Biol Sci,2009,5(2):97-117.
[117]Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-strandedRNA directs the ATP-dependent cleavage of mRNA at21to23nucleotide intervals [J]. Cell,2000,101(1):25-33.
[118]Sui G, Soohoo C, Affar EB, et al. A DNA vector-based RNAitechnology to suppress gene expression in mammalian cells [J].Genetics,2002,99(8):5515-5520.
[119]Coleman MP, Forman D, Bryant H, et al. Cancer survival inAustralia, Canada, Denmark, Norway, Sweden and theUK,1995-2007(the International Cancer Benchmarking Partnership):an analysis of population-based cancer registry data[J]. Lcancet,2011,377(9760):127-138.
[120]Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society ofClinical Oncology clinical practice guideline: update on adjuvantendocrine therapy for women with hormone receptor-positive breastcancer[J]. J Clin Oncol,2010,28(23):37824-3796.
[121]Karavitis J, Zhang M. COX2regulation of breast cancer bonemetastasis [J]. Oncoimmunology,2013,2(3): e23129.
[122]Zhong B, Shen H, Sun X, et al. Additive effects of ulinastatin anddocetaxel on growth of breast cancer xenograft in nude mice andexpression of PGE2, IL-10,and IL-2in primary breast cancer cells[J].Cancer Biother Radiopharm,2012,27(4):252-258.
[123]Karavitis J, Hix LM, Shi YH, et al. Regulation of COX2expressionin mouse mammary tumor cells controls bone metastasis andPGE2-induction of regulatory T cell migration[J]. Plos One,2012,7(9):e46342.
[124]Chimal-Ramirez GK, Espinoza-Sanchez NA, Utrera-Barillas D, etal. MMP1, MMP9, and COX2expressions in promonocytes areinduced by breast cancer cells and correlate with collagendegradation, transformation-like morphological changes inMCF-10A acini, and tumor aggressiveness[J]. Biomed Res Int,2013,279505.
[125]Hannon G.RNA interference [J].Nature,2002,418(6894):244-251.
[126]TR Brummelkamp,R Bernards,R Agami.A system for stableexpression of short interfering RNAs in mammalian cells[J].Science,2002,296(5567):550-553.
[127]Coleman JE, Huentelman MJ, Kasparov S, et al. Efficientlarge-scale production and concentration of HIV-1-based lentiviralvectors for use in vivo. Physiol Genomics,2003,12:221-228.
[128]Deglon N, Tseng JL, Bensadoun JC, et al. Self-inactivatinglentiviral vectors with enhanced transgene expression as potentialgene transfer system in Parkinson's disease. Hum Gene Ther,2000,11:179-190.
[129]Liu H, Xiao J, Yang Y, et al. COX-2expression is correlated withVEGF-C, lymphangiogenesis and lymph node metastasis in humancervical cancer. Microvasc Res,2011,82:131-140.
[130]Frasor J, Danes JM, Komm B,, et al. Profiling of estrogen up-anddown-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogeniccontrol of proliferation and cell phenotype. Endocrinology,2003,144:4562-4574.
[131]Renoir JM, Bouclier C, Seguin A,, et al. Antioestrogen-mediatedcell cycle arrest and apoptosis induction in breast cancer andmultiple myeloma cells. J Mol Endocrinol,2008,40:101-112.
[132]Zheng J and Yao Z. Effect of tamoxifen on apoptosis and drugresistance of breast cancer cells in vitro. Zhonghua Zhong Liu ZaZhi,2000,22:55-57.
[133]Thiantanawat A, Long BJ and Brodie AM. Signaling pathways ofapoptosis activated by aromatase inhibitors and antiestrogens.Cancer Res,2003,63:8037-8050.
[134]Rajput S, Kumar BN, Sarkar S, et al. Targeted apoptotic effects ofthymoquinone and tamoxifen on XIAP mediated Akt regulation inbreast cancer. PLoS One,2013,8: e61342.
[135]赵林,赵杨. RhoC和VEGF在乳腺癌中的表达及临床意义[J].中国肿瘤,2011,20(11):855-858.
[136]刘崇梅,李岳,林明晖,等。VEGF在乳腺癌中的表达及其与ER、PR的相关性研究[J].现代肿瘤医学,2012,20(3):527-529.
[137]Arujo AM, Mendez JC, Coelho AL, et al. Phase II study ofcelcecoxib with cisplatin plus etoposide in extensive-stage small celllung cancer[J]. Cancer Invest,2009,27(4):391-396.
[138]Gasparin G, Meo S, Comella G, et al. The combination of theselective cyclooxygenase-2inhibitor celecoxib with weeklypaclitaxel is a safe and active second-line therapy for non-small celllung cancer: a phase II study with biological corelates[J]. Cancer J,2008,11(3):209-216.
[139]Mallen SR, Essex MN and Zhang R: Gastrointestinal tolerability ofNSAIDs in elderly patients: a pooled analysis of21randomizedclinical trials with celecoxib and nonselective NSAIDs. Curr MedRes Opin,2011,27:1359-1366.
[140]Rezende RM, Paiva-Lima P, Dos Reis WG,, et al. Celecoxibinduces tolerance in a model of peripheral inflammatory pain in rats.Neuropharmacology,2010,59:551-557.
[141]Du G, Yonekubo J, Zeng Y, et al. Design of expression vectors forRNA interference based on miRNAs and RNA splicing. FEBS J,2006273:5421-5427.
[142]Stegmeier F, Hu G, Rickles RJ, et al. A lentiviral microRNA-basedsystem for single-copy polymerase II-regulated RNA interference inmammalian cells. Proc Natl Acad Sci U S A,2005,102：13212-13217.
[143]Samakoglu S, Lisowski L, Budak-Alpdogan T, et al. A geneticstrategy to treat sickle cell anemia by coregulating globin transgeneexpression and RNA interference. Nat Biotechnol,2006,24:89-94.
[144]Emdad L, Lebedeva IV, Su ZZ, et al. Combinatorial treatment ofnon-small-cell lung cancers with gefitinib and Ad.mda-7enhancesapoptosis-induction and reverses resistance to a single therapy. JCell Physiol,2007,210:549-559.
[2]Brauch H and Jordan VC. Targeting of tamoxifen to enhanceantitumour action for the treatment and prevention of breast cancer: the'personalised' approach?[J]. Eur Cancer,2009,45:2274-2283.
[3]Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen andradiotherapy in women with locally excised ductal carcinoma in situ:long-term results from the UK/ANZ DCIS trial. Lancet Oncol,2011,12:21-29.
[4]Roberts CG, Millar EK, O'Toole SA, et al. Identification of PUMA asan estrogen target gene that mediates the apoptotic response totamoxifen in human breast cancer cells and predicts patient outcomeand tamoxifen responsiveness in breast cancer[J]. Oncogene,2011,30:3186-3197.
[5]Garvin S, Nilsson UW and Dabrosin C. Effects of oestradiol andtamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2in breast cancerand endothelial cells. Br J Cancer,2005,93:1005-1010.
[6]Qu Z, Van Ginkel S, Roy AM, et al. Vascular endothelial growth factorreduces tamoxifen efficacy and promotes metastatic colonization anddesmoplasia in breast tumors[J]. Cancer Res,2008,68:6232-6240.
[7]Majeti BK, Lee JH, Simmons BH and Shojaei F. VEGF is animportant mediator of tumor angiogenesis in malignant lesions in agenetically engineered mouse model of lung adenocarcinoma[J]. BMCCancer,2013,13:213.
[8]Chen CT and Hung MC: Beyond anti-VEGF. Dual-targetingantiangiogenic and antiproliferative therapy. Am J Transl Res,2013,5:393-403.
[9]Breinig M, Schirmacher P and Kern MA. Cyclooxygenase-2(COX-2)——a therapeutic target in liver cancer?[J]. Curr Pharm Des,2007,13:3305-3315.
[10]Stasinopoulos I, O'Brien DR, Wildes F, Glunde K and Bhujwalla ZM.Silencing of cyclooxygenase-2inhibits metastasis and delays tumoronset of poorly differentiated metastatic breast cancer cells[J]. MolCancer Res,2007,5:435-442.
[11]Heer P, Sandel MH, Guertens G, et al. Celecoxib inhibits growth oftumors in a syngeneic rat liver metastases model for colorectalcancer[J]. Cancer Chemother Pharmacol,2008,62:811-819.
[12]Narayanan BA, Narayanan NK, Davis L, and Nargi D. RNAinterference-mediated cyclooxygenase-2inhibition prevents prostatecancer cell growth and induces differentiation: modulation ofneuronal protein synaptophysin, cyclin D1, and androgen receptor[J].Mol Cancer Ther,2006,5:1117-1125.
[13]Singh-Ranger G, Salhab M and Mokbel K. The role ofcyclooxygenase-2in breast cancer: review[J]. Breast Cancer ResTreat,2008,109:189-198.
[14]Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelialgrowth factor and angiogenesis[J]. Pharmacol Rev,200456:549-580.
[15]Hasegawa K, Ichikawa W, Fujita T, et al. Expression ofcyclooxygenase-2(COX-2) mRNA in human colorectal adenomas.Eur J Cancer,2001,37:1469-1474.
[16]Kumar BN, Rajput S, Dey KK, et al. Celecoxib alleviatestamoxifen-instigated angiogenic effects by ROS-dependentVEGF/VEGFR2autocrine signaling[J]. BMC Cancer,2013,13:273.
[17]Lacroix I, Lapeyre-Mestre M, Bagheri H, et al. Nonsteroidalanti-inflammatory drug-induced liver injury: a case-control study inprimary care[J]. Fundam Clin Pharmacol,2004,18:201-206.
[18]Rudnick DA, Shikapwashya O, Blomenkamp K and Teckman JH.Indomethacin increases liver damage in a murine model of liverinjury from alpha-1-antitrypsin deficiency[J]. Hepatology,2006,44:976-982.
[19]Park JW, Park JE, Lee JA, Lee CW and Kim CM. Cyclooxygenase-2(COX-2) is directly involved but not decisive in proliferation ofhuman hepatocellular carcinoma cells[J]. Cancer Res Clin Oncol,2006,132:184-192.
[20]Wang R, Wang X, Lin F, Gao P, Dong K and Zhang HZ.shRNA-targeted cyclooxygenase (COX)-2inhibits proliferation,reduces invasion and enhances chemosensitivity in laryngealcarcinoma cells[J]. Mol Cell Biochem,2008,317:179-188.
[21]Lin T, Gu J, Zhang L, et al. Enhancing adenovirus-mediated genetransfer in vitro and in vivo by addition of protamine andhydrocortisone[J]. Gene Med,2003,5:868-875.
[22]Kase S, Osaki M, Honjo S, et al. Expression of cyclooxygenase-1andcyclooxygenase-2in human esophageal mucosa, dysplasia andcarcinoma[J]. Pathobiology,2004,71(2):84-92.
[23]Swami S, Krishnan AV, Moreno J, et al. Calcitriol and genisteinactions to inhibit the prostaglandin pathway: potential combinationtherapy to treat prostate cancer[J]. J Nutr,2007,137(1Suppl):205S-210S.
[24]Denkert C, Winzer KJ, Muller BM, et al. Elevated expression ofcyclooxygenase-2is a negative prognostic factor for disease-freesurvival and overall survival in patients with breast carcinoma[J].Cancer,2003,97(12):2978-2987.
[25]Thill M, Fischer D, Kelling K, et al. Expression of vitamin Dreceptor(VDR), cycloloxygenase-2(COX-2) and15-hydro xyprosta-glandin dehydrogenase (15-PGDH) in benign and malignant ovariantissue and25-hydroxycholecalciferol (25(OH2)D3) and prostaglandinE2(PEG2) serum level in ovarian cancer patient[J].Steroid BiochemMol Biol,2010,121(1-2):387-390.
[26]Subbaramaiah K and Dannenberg AJ. Cyclooxygenase-2: a moleculartarget for cancer prevention and treatment[J]. Trends Pharmacol Sci,2003,24(2):96-102.
[27]Singh-Ranger G, Salhab M and Mokbel K. The role ofcyclooxygenase-2in breast cancer: review[J]. Breast cancer Res Treat,2008,109(2):189-198.
[28]Singh B, Cook KR, Vincent L, et al. Role of COX-2intumorospheres derived from al breast cancer cell line[J]. J Surg Res,2011,168(1): e39-49.
[29]Mauro A, Lipari L, Leone A, et al. Expression of cyclooxygenase-1and cyclooxygenase-2in normal and pathological human oralmucosa[J]. Folia Histochem Cytobiol.2010,48(4):555-563.
[30]Sobolewski C, Cerella C, Dicato M, et al. The role ofcyclooxygenas-2in cell proliferation and cell death in humanmalignancies[J]. Int J Cell Biol,2010,2010:215158.
[31]Sakamoto A, Yokoyama Y, Umemoto M. Clinical implication ofexpression of cyclooxygenase-2and peroxisome proliferatoractivated-receptor g in epithelial ovarian tumours[J]. British Journalof Cancer,2004,91(14),633–638.
[32]Ghosh N, Chaki R, Mandal V, et al. COX-2as a target for cancertherapy[J]. Pharmacological Reports,2010,62(2):233-244.
[33]Joki T，Heese O，Nikas DC，et al. Expression of cyclooxygenas-2(COX-2) in human glioma and in vitro inhibition by a specific COX-2inhibitor,NS2398[J]. Cancer Res,2000,60(17):4926-4931.
[34]Mehar A, Macanas Pirard P, Mizokami AT, et al. The effects ofcyclooxygenase-2expression in prostate cancer cells: modulation ofresponse to cytotoxic agents[J]. J Pharmacol Exp Ther,2008,324(3):1181-1187.
[35]Frasor J, Weaver AE, Pradhan M, et al. Synergistic up-regulation ofprostaglandin E synthase expression in breast cancer cells by17beta-estradiol and proinflammatory cytokines[J]. Endocrinology,2008,149(12):6272-6279.
[36]Oshima H, Oshima M. The inflammatory network in thegastrointestinal tumor microenvironment: lessons from mouse models[J]. Gastroenterol,2012,47(2):97-106.
[37]Khan Z, Khan N, Tiwari RP, et al. Biology of COX-2: An Applicationin Cancer Therapeutics[J]. Current Drug Targets,2011,12(7):1082-1093.
[38]Athanassiadou P, Grap sa D, Athanassiades P, et al. The prognosticsignificance of COX-2and survivin expression in ovaian cancer[J].Pathol Res Pract,2008,204(4):241-249.
[39]Daikoku T, Tranguch S, Trofimova N, et al. Cyclooxygenase-1isoverexpressed in multiple genetically engineered mouse models ofepithelial ovarian cancer[J]. Cancer Res,2006,66(5):2527-2531.
[40]Ko SH, Choi GJ, Lee JH, et al. Differential effects of selectivecyclooxygenase-2inhibitors in inhibiting proliferation and inductionof apoptosis in oral squamous cell carcinoma[J]. OncolRep,2008,19(2):425-433.
[41]Basu GD, Pathangey LB, Tinder TL, et al. Cyclooxygenase-2inhibitor induces apoptosis in breast cancer cells in an in vivo modelof spontaneous metastatic breast cancer[J].Mol Cancer Res,2004,2(11):632-642.
[42]杨晓文,崔明,王世清,等.乳腺癌组COX-2和Bcl-2蛋白表达及其临床意义[J].中华肿瘤防治杂志,2009,16(4):295-298.
[43]Elder DJ, Halto n DE, Cr ew T E, et al. Apoptosis induction andcyclooxygenase-2regulation in human colorectal adenoma andcarcinoma cell lines by the cy cloox genease-2-selective no nsteroedalanti-inflammatory drugs NS-398. I nt J Cancer,2000,86(4):553-560.
[44]Kundu N, Smyth MJ, Samsel L, et al. Cyclooxygenase inhibitorsblock cell growth, increase ceramide and inhibit cell cycle[J]. BreastCancer Res Treat,2002,76(1):57-64.
[45]Trifan OC, Smith RM, Thompson BD, et al. Overexpression ofcyclooxygenase-2induceds cell cycle arrest[J]. J Biol Chem,1999,274(48):34141-34147
[46]Lee JS, Choi YD, Lee JH, et al. Expression of cyclooxygenase-2inepithelial ovarian tumors and its relation to vascular endothelialgrowth factor and p53expression[J]. Int J Gynecol Cancer,2006,16Suppl1:247-253.
[47]徐晓辉,申爱荣,王志红. COX-2、VEGF及MMP-9蛋白在上皮性卵巢癌组织中的表达及意义[J].肿瘤基础与临床,2010,23(6)：467-469.
[48]Ferrandina G,Ranelletti FO, Martinelli E et al. Cyclooxygenase-2(Cox-2)expression and resistance to platinum versusplatinum/paclitaxel containing chemotherapy in advanced ovariancancer[J]. BMC Cancer,2006,11(6):182.
[49]Raspollini MR, Amunni G, Villanucci A, et al. COX-2status inrelation to tumor microvessel density and VEGF expression: analysisin ovarian carcinoma patients with low versus high survival rates[J].Oncol Rep.2004,11(2):309-313.
[50]Fujimoto J Toyoki H, Sakaguchi H, et al. Clinical implications ofexpression of cyclooxygenase-2related to angiogenesis in ovariancancer[J]. Oncol Rep,2006,15(1):21–25.
[51]Form DM, Auerbach R. PGE2and angiogenesis[J]. Proc Soc ExpBiol Med,1983,172(2):214–218.
[52]Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN.Cyclooxygenase regulates angiogenesis induced by colon cancercells[J]. Cell,1998,93(5):705–716.
[53]Zhu YM, Azahri NS, Yu DC, et al. Effects of COX-2inhibition onexpression of vascular endothelial growth factor and interleukin-8inlung cancer cells[J]. BMC Cancer,2008,8(7):218
[54]Wu Y, Wei zw, He YL. Efficacy of adjuvant XELOX and FOLFOX6chemotherapy after D2dissection for gastric cancer[J]. World JGastroenterol,2013,19(21):3309-3315.
[55]Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancercyclooxygenase-2-dependent invasion is mediated by CD44[J]. JBiol Chem,2011,276(24):20809-20812.
[56]Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact withosteoblasts to support osteoclast formation [J]. Endocrinology,1999;140(10):4451-4458.
[57]Tsujii M, Kawano S, Tsuji S, Saw aoka, et al. Cyclooxygeneaseregulates angiogenesis induced by coloncancer cells. Cell,1998,93(2):705-716.
[58]Lim SC. Role of COX-2, VEGF and cyclin D1in mammaryinfiltrating duct carcinoma [J]. Oncol Rep,2003,10(5):1241-1249.
[59]Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancercyclooxygenase-2-dependent invasion is mediated by CD44[J]. JBiol Chem,2001;276(24):20809-20812.
[60]Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell anddendritic cell function is related to Cyclooxygenase-2overexpressionand prostaglandin E (2) secretion in patients with breast cancer [J].Ann Surg Oncol,2004;11(3):328-339.
[61]Stolina M, Sharma S, Lin Y, et al. Specific inhibition ofcyclooxygenase-2restores antitumor reactivity by altering the balanceof IL-10and IL-12synthesis [J]. Immunology,2000;164(1):361-370.
[62]Pockaj BA, Basu GD, Pat hangey LB, et al. Reduced T-cell anddendritic cell function is related to cyclooxygenase-2overexpressionand prostag land ine secretion in patients with breast cancer[J]. AnnSurg Oncol,2004,11(3):328-329.
[63]Banerjec S, Bueso-Ramos C, Aggarwal BB. Suppression of7,12-dimethylbenz (a) anthracene-induced mammary carcinogensis inrats by reveratrol: role of nuclear factor-kappa B, Cyclooxygenase-2,and matrix metaloprotease9[J]. Cancer Res,2002;62(17):4945-4954.
[64]Wiese FW, Thompson PA, Kadlubar FF, et al. Carcinogen substratespecificity of human COX-1and COX-2[J]. Carcinogenesis,2001;22(1):5-10.
[65]Stolina M, Shanna S, Lin Y， et al. Secific inhibition ofcyclooxygenase-2restores antiturcar reactivity by altering the balanceof IL-10and II-12synthesis[J]. J Immunol,2000,164(1):361.
[66]Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterifiedarachidonic acid signals apoptosis [J]. Proc Natl Acad Sci USA,2000;97(21):11280-11285.
[67]Brueggenmeier RW, Quinn AL, Parrett ML. Correlation of aromataseand cyclooxygenase gene expression in human breast cancerspecimens [J]. Cancer Lett,1999;140(1-2):27-35.
[68]Oliveira VM, Piato S, Silva MA. Correlat ion of cyclooxygenase-2and aromatase immuno-histochemical expression in invasive ductalcarcinoma,ductal carcinoma in situ, and adjacent normal epithelium[J]. Breast Cancer ResTreat,2006,95(3):235-241.
[69]Sa lhabM, Singh-Range rG, Moke lb R, et al Cyc looxygenase-2mRNA expression correlates with a rom a tase expression in hum anbreast cancer[J]. Surg Oncol,2007,96(5):424-428
[70]Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance ofelevaluted cyclooxygenase-2expression in breast cancer [J]. CancerRes,2002;62(3):632-635.
[71]Hee S, Hyeong M, Wonshik H, et al. COX2overexpression is aprognostic marker for Stage III breast cancer[J]. Breast Cancer ResTreat (2012)132:51–59
[72]Barnes N,Haywood P,Flint P, et al.Survivin expression in in situ andinvasive breast cancer relates to COX-2expression and DCISrecurrence [J]. Br J Cancer,2006,94:253-258.
[73]Sivula, Talvensaari, Johan, et al. Association of cyclooxygenase-2and matrix metalloproteinase-2expression in human breast cancer[J].Breast Cancer Res Treat,2005,89(3):215-220.
[74]吴骥,管小青,顾书成,等. COX-2及Ki67在乳腺癌浸润性导管癌组织中的表达及临床意义[J].中国肿瘤外科杂志,2013,10(5):296-299.
[75]李莉,祝峙,方国恩等. COX-2和P53在乳腺癌组织中的表达及其相关性[J].中华肿瘤防治杂志,2006,13(4):287-289.
[76]王西京,代志军,赵世平,等.乳腺癌组织中环氧化酶-2的表达及其意义[J].肿瘤防治杂志,2004,11(12):1261-1263.
[77]Kelly LM, Hill AD, Kennedy S, et al. Lack of prognostic effect ofCox-2expression in primary breast cancer on short-term follow-up.Eur J Surg Oncol,2003,29:707–710.
[78]Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJCOX-2expression is associated with an aggressive phenotype inductalcarcinoma in situ. Br J Cancer,2004,90:423–429.
[79]Mohammad AM, Abdel HA, Abdel W, et al. Expression ofcyclooxygenase-2and12-lipoxygenase in human breast cancer andtheir relationship with HER-2/neu and hormonal receptors: impact onprognosis and therapy. Indian J Cancer,2006,43:163–168
[80]Denkert C, Winzer KJ, Muller BM, et al. Elevated expression ofcyclooxygenase-2is a negative prognostic factor for disease freesurvival and overall survival in patients with breast carcinoma[J].Cancer,2003,97:2978–2987.
[81]Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase2expression is associated with angiogenesis and lymph node metastasisin human breast cancer[J]. Clin Pathol,2002,55:429–434.
[82]O’Connor JK, Avent J, Lee RJ, et al. Cyclooxygenase-2expressioncorrelates with diminished survival in invasive breast cancer treatedwith mastectomy and radiotherapy[J]. Radiat Oncol Biol Phys,2004,58:1034–1040.
[83]Hee SK, Hyeong GM, Wonshik H, et al. COX2overexpression is aprognostic marker for Stage III breast cancer[J]. Breast Cancer ResTreat,2012,132:51-59.
[84]Sym SJ, Chang HM, Ryn MH, et al. Neoadjuvant docetaxel,capecitabine and cisplain(DXP) in patients with unresectable locallyadvanced or metastatic gastric cancer[J]. Ann Surg Oncol,2010,17(4):1024-1032.
[85]Haffty B, Yang Q, Moran M, et al. Estrogendependent prognosticsignificance of cyclooxygenase-2expression in early-stage invasivebreast cancers treated with breast conserving surgery and radiation.Int J Radiat Oncol Biol Phys,2008,71:1006–1013.
[86]Park K, Han S, Shin E, Kim HJ, Kim JY.Cox-2expression on tissuemicroarray of breast cancer[J]. Eur J Surg Oncol,2006,32:1093–1096.
[87]Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancermetastasis to the brain[J]. Nature,2009,459:1005–1009.
[88]Singh B, Berry JA, Shoher A, et al. COX-2involvement in breastcancer metastasis to bone[J]. Oncogene,2007,26:3789–3796.
[89]肖锋,顾春燕,姚建国,等. COX-2和VEGF-C基因在乳腺癌良恶性病变中的表达研究[J].实用肿瘤杂志,2011,26(6):573-576.
[90]王彬,聂国庆,张超,等. COX-2与突变型P53蛋白在乳腺癌组织中的表达及临床意义[J].实用肿瘤杂志,2010,25(3):295-299.
[91]管小青,顾书成,吴骥,等.生存素和COX-2在乳腺癌复发及转移癌组织的表达[J].江苏医药,2012,38(1):33-35.
[92]王群,余明华,王耕,等. DLL4、COX-2和MMP2在乳腺癌组织中的表达及临床意义[J].临床肿瘤学杂志,2012,9(17):814-817.
[93]Davies G, Salter J, Hill M, et al. Correlation betweencyclooxygenase-2expression and angiogenesis in human breastcancer [J]. Clin Cancer Res,2003,9(7):2651-2656.
[94]Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2expression inhuman breast cancers and adjacent ductal carcinoma in situ[J]. CancerRes,2002,62(6):1676-1681.
[95]Rao PN, Grover RK. Apricoxib. A COX-2inhibitor for the potentialtreatment of pain and cancer[J]. The investigational drugs journal(IDrugs),2009,12(11):711-722.
[96]Abbadessa G, Spaccamiglio A, Sartori ML, et al. The aspirinmetabolite, salicylate, inhibits7,12-dimethylbenz[a] anthracene-DNAadduct formation in breast cancer cells[J]. Int J Oncol,2006,28(5):1131-1140.
[97]Abou-Issa HM, AIshafie GA, Seibert K, et al. Dose-response effectsof the COX-2inhibitor, celecoxib, on the chemoprevention ofmammary carcinogenesis[J]. Anticancer Res,2001,21(5):3425-3432.
[98]Khuder SA, Mutgi AB. Breast cancer and NSAIDuse:ameta-anaylysis[J]. Br J Cancer,2001,84(9):1188-1192.
[99]Sharpe CR, Collet JP, McNutt M, et al. Nested case control study ofthe effects of non-steroidal anti-inflammatory drugs on breast cancerrisk and stage[J]. Br J Cancer,2000,83(1):112-120.
[100]Harris RE, Kasbari Farrar WB. Prospective study of nonsteroidalanti-inflammatiory drugs and breast cancer[J]. Oncol Rep,1996,6:71-73.
[101]Alshafie GA, Abou-Issa HM, Seibert K and Harris RE.Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2inhibitor, in a rat mammary tumor model[J]. Oncol Rep,2000,7(6):1377-1381.
[102]Harris RE, Alshafie GA, Abou-Issa H and Seibert K.Chemoprevention of breast cancer in rats by celecoxib, acyclooxygenase-2inhibitor[J]. Cancer Res,2000,60(8):2101-2103.
[103]Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2inhibition: effects on tumor growth, cell cycling andlymphangiogenesis in a xenograft model of breast cancer[J]. Br JCancer,2007,96(4):575-582.
[104]Yoshinaka R, Shibata MA, Morimoto J, et al. COX-2inhibitorcelecoxib suppresses tumor growth and lung metastasis of a murinemammary cancer[J]. Anticancer Res,2006.26(6B):4245-4254.
[105]Moreno J, Krishnan AV, Swami S, et al. Regulation ofprostaglandin metabolism by calcitriol attenuates growth stimulationin prostate cancer cells[J]. Cancer Res,2005,65(17):7917-7925.
[106]Kang HF, Wang XJ, Liu XX, et al. Chemopreventive effect ofcelecoxib against DMBA-induced breast cancer and itsmechanism[J]. Nan Fang Yi Ke Da Xue Xue Bao,2006,26(11):1599-1602.
[107]何美蓉,林劲松,宋于刚.选择性COX-2抑制剂对大鼠胃溃疡微血管形成的影响及机制[J].广东医学,2008,29(3):379-381.
[108]李根,陈虹.选择性COX-2抑制剂塞来昔布抗癌作用研究进展[J].Journal of Logistics University of CAPF(Medical Sciences),2012,21(3):214-220.
[109]Xiuling Lu, Melissa D. Howard, Dominique R. Talbert, et al.Nanoparticles Containing Anti-inflammatory Agents as ChemotherapyAjuvants: Role of Plasma Esterases in Drug Release [J]. AAPSJ.Mar2009,11(1):120-122.
[110]Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular eventsassociated with rofecoxib in a colorectal Adenoma chemopreventiontrial[J]. N Engl J Med,2005,352(11):1092-1102.
[111]Chen LC, Ashcroft DM. Risk of myocardial infarction associatedwith selective COX-2inhibitors meta-analysis of randomisedcontrolled trials[J].Pharmacoepeidemiol Drug Saf,2007,16(7):762-772.
[112]Farooq M, Haq I, Qureshi AS. Cardiovescular risks of COXinhibition: current perspectives [J]. Expert Opin Pharmacother,2008,9(8):1311-1319.
[113]钟英强,黄花荣,刘娟,等. siRNA沉默COX-2基因对人胰腺癌Capan-2细胞增殖、细胞周期、凋亡和成瘤能力的影响[J].中国病理生理杂志,2011,27(7):1290-1296.
[114]药立波.医学分子生物学[M].北京:人民卫生出版社,2004：290-292.
[115]Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAsand siRNAs[J]. Cell,2009,136(4):642-655.
[116]Nagvi AR,Islam MN, Choudhury NR, et al. the fascinating worldof RNA interference[J].Int J Biol Sci,2009,5(2):97-117.
[117]Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-strandedRNA directs the ATP-dependent cleavage of mRNA at21to23nucleotide intervals [J]. Cell,2000,101(1):25-33.
[118]Sui G, Soohoo C, Affar EB, et al. A DNA vector-based RNAitechnology to suppress gene expression in mammalian cells [J].Genetics,2002,99(8):5515-5520.
[119]Coleman MP, Forman D, Bryant H, et al. Cancer survival inAustralia, Canada, Denmark, Norway, Sweden and theUK,1995-2007(the International Cancer Benchmarking Partnership):an analysis of population-based cancer registry data[J]. Lcancet,2011,377(9760):127-138.
[120]Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society ofClinical Oncology clinical practice guideline: update on adjuvantendocrine therapy for women with hormone receptor-positive breastcancer[J]. J Clin Oncol,2010,28(23):37824-3796.
[121]Karavitis J, Zhang M. COX2regulation of breast cancer bonemetastasis [J]. Oncoimmunology,2013,2(3): e23129.
[122]Zhong B, Shen H, Sun X, et al. Additive effects of ulinastatin anddocetaxel on growth of breast cancer xenograft in nude mice andexpression of PGE2, IL-10,and IL-2in primary breast cancer cells[J].Cancer Biother Radiopharm,2012,27(4):252-258.
[123]Karavitis J, Hix LM, Shi YH, et al. Regulation of COX2expressionin mouse mammary tumor cells controls bone metastasis andPGE2-induction of regulatory T cell migration[J]. Plos One,2012,7(9):e46342.
[124]Chimal-Ramirez GK, Espinoza-Sanchez NA, Utrera-Barillas D, etal. MMP1, MMP9, and COX2expressions in promonocytes areinduced by breast cancer cells and correlate with collagendegradation, transformation-like morphological changes inMCF-10A acini, and tumor aggressiveness[J]. Biomed Res Int,2013,279505.
[125]Hannon G.RNA interference [J].Nature,2002,418(6894):244-251.
[126]TR Brummelkamp,R Bernards,R Agami.A system for stableexpression of short interfering RNAs in mammalian cells[J].Science,2002,296(5567):550-553.
[127]Coleman JE, Huentelman MJ, Kasparov S, et al. Efficientlarge-scale production and concentration of HIV-1-based lentiviralvectors for use in vivo. Physiol Genomics,2003,12:221-228.
[128]Deglon N, Tseng JL, Bensadoun JC, et al. Self-inactivatinglentiviral vectors with enhanced transgene expression as potentialgene transfer system in Parkinson's disease. Hum Gene Ther,2000,11:179-190.
[129]Liu H, Xiao J, Yang Y, et al. COX-2expression is correlated withVEGF-C, lymphangiogenesis and lymph node metastasis in humancervical cancer. Microvasc Res,2011,82:131-140.
[130]Frasor J, Danes JM, Komm B,, et al. Profiling of estrogen up-anddown-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogeniccontrol of proliferation and cell phenotype. Endocrinology,2003,144:4562-4574.
[131]Renoir JM, Bouclier C, Seguin A,, et al. Antioestrogen-mediatedcell cycle arrest and apoptosis induction in breast cancer andmultiple myeloma cells. J Mol Endocrinol,2008,40:101-112.
[132]Zheng J and Yao Z. Effect of tamoxifen on apoptosis and drugresistance of breast cancer cells in vitro. Zhonghua Zhong Liu ZaZhi,2000,22:55-57.
[133]Thiantanawat A, Long BJ and Brodie AM. Signaling pathways ofapoptosis activated by aromatase inhibitors and antiestrogens.Cancer Res,2003,63:8037-8050.
[134]Rajput S, Kumar BN, Sarkar S, et al. Targeted apoptotic effects ofthymoquinone and tamoxifen on XIAP mediated Akt regulation inbreast cancer. PLoS One,2013,8: e61342.
[135]赵林,赵杨. RhoC和VEGF在乳腺癌中的表达及临床意义[J].中国肿瘤,2011,20(11):855-858.
[136]刘崇梅,李岳,林明晖,等。VEGF在乳腺癌中的表达及其与ER、PR的相关性研究[J].现代肿瘤医学,2012,20(3):527-529.
[137]Arujo AM, Mendez JC, Coelho AL, et al. Phase II study ofcelcecoxib with cisplatin plus etoposide in extensive-stage small celllung cancer[J]. Cancer Invest,2009,27(4):391-396.
[138]Gasparin G, Meo S, Comella G, et al. The combination of theselective cyclooxygenase-2inhibitor celecoxib with weeklypaclitaxel is a safe and active second-line therapy for non-small celllung cancer: a phase II study with biological corelates[J]. Cancer J,2008,11(3):209-216.
[139]Mallen SR, Essex MN and Zhang R: Gastrointestinal tolerability ofNSAIDs in elderly patients: a pooled analysis of21randomizedclinical trials with celecoxib and nonselective NSAIDs. Curr MedRes Opin,2011,27:1359-1366.
[140]Rezende RM, Paiva-Lima P, Dos Reis WG,, et al. Celecoxibinduces tolerance in a model of peripheral inflammatory pain in rats.Neuropharmacology,2010,59:551-557.
[141]Du G, Yonekubo J, Zeng Y, et al. Design of expression vectors forRNA interference based on miRNAs and RNA splicing. FEBS J,2006273:5421-5427.
[142]Stegmeier F, Hu G, Rickles RJ, et al. A lentiviral microRNA-basedsystem for single-copy polymerase II-regulated RNA interference inmammalian cells. Proc Natl Acad Sci U S A,2005,102：13212-13217.
[143]Samakoglu S, Lisowski L, Budak-Alpdogan T, et al. A geneticstrategy to treat sickle cell anemia by coregulating globin transgeneexpression and RNA interference. Nat Biotechnol,2006,24:89-94.
[144]Emdad L, Lebedeva IV, Su ZZ, et al. Combinatorial treatment ofnon-small-cell lung cancers with gefitinib and Ad.mda-7enhancesapoptosis-induction and reverses resistance to a single therapy. JCell Physiol,2007,210:549-559.